logo
Plus   Neg
Share
Email

Merck Says FDA Accepts For Review Two NDAs For Doravirine - Quick Facts

Merck & Co. Inc. (MRK) said that the U.S. Food and Drug Administration has accepted for review two New Drug Applications or NDAs for doravirine, the company's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults.

The NDAs include data for doravirine (DOR) as a once-daily tablet for use in combination with other antiretroviral agents, and for use of doravirine with lamivudine or 3TC, and tenofovir disoproxil fumarate or TDF in a once-daily fixed-dose combination single tablet as a complete regimen (DOR/3TC/TDF).

Merck noted that the FDA has set a target action date of October 23, 2018, for both applications under the Prescription Drug User Fee Act or PDUFA.

The NDAs are based upon the findings at Week 48 of two ongoing Phase 3 trials, DRIVE-FORWARD and DRIVE-AHEAD, evaluating the efficacy and safety of doravirine and the fixed-dose combination regimen of DOR/3TC/TDF, respectively.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug major Roche Holding AG reported Wednesday higher sales in its first nine months of fiscal 2018, with growth in Pharmaceuticals sales in all regions except Europe. Diagnostics Division also recorded higher sales in all regions. Looking ahead to fiscal 2018, Roche confirmed its outlook for higher results at constant exchange rates. Online-video streaming service Netflix Inc. (NFLX), Tuesday reported a third-quarter profit that surged from last year as revenues increased 34% driven largely by strong subscriber additions. Shares surged nearly 12 percent in the after-hours trading. Netflix added 6.96 million subscribers globally... Despite opposition from the pharmaceutical industry, President Donald Trump's administration has proposed a new rule requiring companies to include the prices for prescription drug and biological products in their television advertisements.
Follow RTT